Editorial: Management of Immune-Related Adverse Events for Patients Undergoing Treatment With Checkpoint Inhibitors

Editorial: Management of Immune-Related Adverse Events for Patients Undergoing Treatment With Checkpoint Inhibitors

Bibliographic Details
Main Author:	Bernardo Leon Rapoport
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2019-05-01
Series:	Frontiers in Oncology
Subjects:	immune related adverse effects colitis pneumonitis anti CTLA 4 anti-PD 1
Online Access:	https://www.frontiersin.org/article/10.3389/fonc.2019.00365/full

Similar Items

The Heart of the Matter: Immune Checkpoint Inhibitors and Immune-Related Adverse Events on the Cardiovascular System
by: Chase E. Green, et al.
Published: (2023-12-01)

Pulmonary Toxicities Associated With the Use of Immune Checkpoint Inhibitors: An Update From the Immuno-Oncology Subgroup of the Neutropenia, Infection & Myelosuppression Study Group of the Multinational Association for Supportive Care in Cancer
by: Bernardo L. Rapoport, et al.
Published: (2021-10-01)

Clinical features, diagnostic challenges, and management strategies in checkpoint inhibitor-related pneumonitis
by: Chuzi S, et al.
Published: (2017-06-01)

Mucocutaneous adverse events to immune checkpoint inhibitors
by: Fiorinda Muhaj, et al.
Published: (2023-03-01)

Treatment-Related Adverse Events of Combination Immune Checkpoint Inhibitors: Systematic Review and Meta-Analysis
by: Robin Park, et al.
Published: (2020-03-01)

Cutaneous Adverse Events Associated with Immune Checkpoint Inhibitors: A Review Article
by: Chieh-Hsun Chen, et al.
Published: (2022-04-01)

Cardiotoxicity of FDA-approved immune checkpoint inhibitors: A rare but serious adverse event
by: Abdulrazzak Zarifa, et al.
Published: (2018-10-01)

Molecular Mechanisms of Cutaneous Immune-Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitors
by: Yi-Shan Teng, et al.
Published: (2023-07-01)

Immune checkpoint inhibitors, endocrine adverse events, and outcomes of melanoma
by: Hanna Karhapää, et al.
Published: (2022-02-01)

Central Nervous System Demyelination Associated With Immune Checkpoint Inhibitors: Review of the Literature
by: Marcos C. B. Oliveira, et al.
Published: (2020-12-01)

Thyroid-related adverse events induced by immune checkpoint inhibitors
by: Alexandra Chera, et al.
Published: (2022-09-01)

Biomarkers for Immune Checkpoint Inhibitor-Mediated Tumor Response and Adverse Events
by: Yoshiyuki Nakamura
Published: (2019-05-01)

Overcoming the cardiac toxicities of cancer therapy immune checkpoint inhibitors
by: Omoruyi Credit Irabor, et al.
Published: (2022-09-01)

Role of Infliximab in Immune Checkpoint Inhibitor-Induced Pneumonitis
by: Kathryn A. Lai, et al.
Published: (2020-11-01)

Radiation recall pneumonitis from immune checkpoint inhibitors after extra pulmonary radiation
by: Leslie E. Kao, et al.
Published: (2023-10-01)

CANDIED: A Pan-Canadian Cohort of Immune Checkpoint Inhibitor-Induced Insulin-Dependent Diabetes Mellitus
by: Thiago P. Muniz, et al.
Published: (2021-12-01)

Editorial: Decoding checkpoint inhibitor-induced immune-related adverse events, volume II
by: Deborah L. Burnett, et al.
Published: (2023-10-01)

Achilles’ Heel of currently approved immune checkpoint inhibitors: immune related adverse events
by: Ting Yan, et al.
Published: (2024-02-01)

Immune Dysregulation in Cancer Patients Undergoing Immune Checkpoint Inhibitor Treatment and Potential Predictive Strategies for Future Clinical Practice
by: Ronald Anderson, et al.
Published: (2018-03-01)

Immune-Related Adverse Events Due to Cancer Immunotherapy: Immune Mechanisms and Clinical Manifestations
by: Silvia Casagrande, et al.
Published: (2024-04-01)

Immuno-related endocrinopathy in patients treated with immune checkpoint inhibitors
by: D. I. Yudin, et al.
Published: (2020-07-01)

Adverse Events Following Administration of Anti-CTLA4 Antibody Ipilimumab
by: Amirali Karimi, et al.
Published: (2021-03-01)

Pancreatic Adverse Events Associated With Immune Checkpoint Inhibitors: A Large-Scale Pharmacovigilance Analysis
by: Yue Zhang, et al.
Published: (2022-04-01)

Immune Checkpoint Inhibitors in Malignant Pleural Mesothelioma: A Systematic Review and Meta-Analysis
by: Maria Gemelli, et al.
Published: (2022-12-01)

The Continuum of Thyroid Disorders Related to Immune Checkpoint Inhibitors: Still Many Pending Queries
by: Maria V. Deligiorgi, et al.
Published: (2021-10-01)

Immune checkpoint inhibitors associated cardiovascular immune-related adverse events
by: Wonyoung Jo, et al.
Published: (2024-02-01)

Efficacy of metformin in combination with immune checkpoint inhibitors (anti-PD-1/anti-CTLA-4) in metastatic malignant melanoma
by: Muhammad Zubair Afzal, et al.
Published: (2018-07-01)

Cardiac arrhythmias associated with immune checkpoint inhibitors: A comprehensive disproportionality analysis of the FDA adverse event reporting system
by: Feifei Wang, et al.
Published: (2022-11-01)

Opportunistic autoimmune disorders potentiated by immune-checkpoint inhibitors anti-CTLA-4 and anti-PD-1
by: Yi-Chi eKong, et al.
Published: (2014-05-01)

Changes of peripheral T cell subsets in melanoma patients with immune-related adverse events
by: Benjamin Müller, et al.
Published: (2023-04-01)

Combination checkpoint inhibitors for treatment of non-small-cell lung cancer: an update on dual anti-CTLA-4 and anti-PD-1/PD-L1 therapies
by: Sonam Puri, et al.
Published: (2020-01-01)

Skin Manifestation Induced by Immune Checkpoint Inhibitors
by: Yamamoto T
Published: (2022-05-01)

Checkpoint inhibitor responses can be regulated by the gut microbiota – A systematic review
by: Mariam Zeriouh, et al.
Published: (2023-09-01)

Immunotherapy for Melanoma: The Significance of Immune Checkpoint Inhibitors for the Treatment of Advanced Melanoma
by: Taku Fujimura, et al.
Published: (2022-12-01)

Immune Checkpoint Inhibitors in Acute Myeloid Leukemia: A Meta-Analysis
by: Marina Gómez-Llobell, et al.
Published: (2022-04-01)

Effect of gut microbiota on immune checkpoint inhibitor (ICI) based cancer immunotherapy
by: A. Y. P. Perera, et al.
Published: (2021-12-01)

Severe autoimmune hemolytic anemia following immunotherapy with checkpoint inhibitors in two patients with metastatic melanoma: a case report
by: Tanja Fetter, et al.
Published: (2024-03-01)

Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment
by: Ming Yi, et al.
Published: (2019-03-01)

Immune-related adverse events following administration of anti-cytotoxic T-lymphocyte-associated protein-4 drugs: a comprehensive systematic review and meta-analysis
by: Xu H, et al.
Published: (2019-07-01)

The safety and tolerability of combined immune checkpoint inhibitors (anti-PD-1/PD-L1 plus anti-CTLA-4): a systematic review and meta-analysis
by: Lihu Gu, et al.
Published: (2019-06-01)